Wall Street expects a year-over-year decline in earnings on higher revenues when Bristol Myers Squibb (BMY) reports results for the quarter ended December 2024. While this widely-known consensus ...

"But again, some of it comes down to finances, what you can do and is it worth bringing someone in for the sake of it? "Again, I'll be transparent, it's quite unlikely we're going to do anything." ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks discussed by Jim Cramer with insights on the DeepSeek AI sell-off.

We kick off our Adobe Women’s FA Cup campaign at home to Bristol City Women on Wednesday night. The match kicks off at 7.45pm at Mangata Pay UK Stadium, Meadow Park, and if you haven’t got tickets you ...

Our Gunners are set to commence their Adobe Women's FA Cup journey with a fourth-round clash against Bristol City Women this Wednesday evening. The fixture, which was postponed due to a frozen pitch ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $39.00. Terence Flynn’s rating is based on ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients.